ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "large vessel vasculitis"

  • Abstract Number: 1419 • ACR Convergence 2021

    Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis

    Mwidimi Ndosi1, Celia Almeida2, Jill Dawson3, Emma Dures2, Rosemary Greenwood4, Catherine Guly5, Sarah Mackie6, Alison Bromhead4, Steve Stern4 and Joanna Robson2, 1University of the West of England, Bristol, Filton, United Kingdom, 2UWE Bristol, Bristol, United Kingdom, 3University of Oxford, Oxford, 4University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, 5University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, 6School of Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…
  • Abstract Number: 1868 • ACR Convergence 2021

    Neutrophil Extracellular Trap Formation in Patients with Vasculitis

    Despina Michailidou1, Runa Kuley1, Tomas Mustelin2, David Cuthbertson3, Peter Grayson4, Nader Khalidi5, CURRY LEE MD KOENING6, Carol Langford7, Carol McAlear8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Ulrich Specks12, Antoine Sreih8, Kenneth Warrington13, Paul Monach14, Peter Merkel15 and Christian Lood2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2University of Washington, Seattle, WA, 3Health Informatics Institute, University of South Florida, South Florida, FL, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 5McMaster University, Hamilton, ON, Canada, 6LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, 7Cleveland Clinic, Moreland Hills, OH, 8Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 9Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 10Mount Sinai Hospital, Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN, 13Mayo Clinic, Rochester, Minnesota, 14Brigham and Women's Hospital, Boston, MA, 15University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Neutrophil extracellular trap (NET) formation, the extrusion of chromatin and granular components from activated neutrophils, is essential in host defense. However, NET formation has…
  • Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium

    A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)

    Ellen Go1, Simon Eng 2, David Cabral 3 and Rae Yeung 1, 1The Hospital for Sick Children, Toronto, Canada, 2Toronto, Canada, 3BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

    Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
  • Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium

    Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations

    Uptej Khalsa1 and Imelda Balboni 1, 1Stanford University, Palo Alto, California

    Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
  • Abstract Number: 2690 • 2019 ACR/ARP Annual Meeting

    Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience

    Ingeborg Sacksen 1, Elizabeth Jernberg 1, Scott Pollock 2, Jean Liew 3, Sarah Chung 2, R Eugene Zierler 3 and Alison Bays2, 1University of Washington Division of Rheumatology, Seattle, 2University of Washington Division of Rheumatology, Seattle, WA, 3University of Washington, Seattle, WA

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults and if untreated, may  result in visual impairment. Although the gold…
  • Abstract Number: 2692 • 2019 ACR/ARP Annual Meeting

    Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden

    Pavlos Stamatis1, Moman Mohammad 1, Peter Merkel 2, Martin Englund 3, Carl Turesson 4, David Erlinge 1 and Aladdin Mohammad 1, 1Lund University, Lund, Skane Lan, Sweden, 2University of Pennsylvania, Philadelphia, PA, 3Lund University, Lund, Sweden, 4Lund University, Malmö, Sweden

    Background/Purpose: The aim of this study was to estimate the incidence rate and prevalence of coronary artery diseases (CAD) in patients with temporal artery positive…
  • Abstract Number: 2919 • 2019 ACR/ARP Annual Meeting

    Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

    Tomoyuki Mutoh1, Tsuyoshi Shirai 1, Tomonori Ishii 2, Yuko Shirota 3, Hideo Harigae 1 and Hiroshi Fujii 1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Tohoku University Hospital, Sendai, Japan, 3Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan

    Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in…
  • Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting

    Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis

    K Bates Gribbons1, Cristina Ponte 2, Anthea Craven 3, David Cuthbertson 4, Simon Carette 5, Gary S. Hoffman 6, Nader A. Khalidi 7, Curry L. Koening 8, Carol Langford 9, Kathleen Maksimowicz-McKinnon 10, Carol A. McAlear 11, Paul Monach 12, Larry Moreland 13, Christian Pagnoux 14, Kaitlin Quinn 15, Joanna Robson 16, Philip Seo 17, Antoine Sreih 18, Ravi Suppiah 19, Kenneth Warrington 20, Steven Ytterberg 21, Raashid Luqmani 3, Richard Watts 22, Peter Merkel 18 and Peter C. Grayson 23, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, 3University of Oxford, Oxford, United Kingdom, 4University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 6Cleveland Clinic Foundation, Cleveland, OH, 7McMaster University, Hamilton, ON, Canada, 8University of Utah Hospital, Salt Lake City, UT, 9Cleveland Clinic, Cleveland, OH, 10Henry Ford Hospital, Wayne State University, Detroit, MI, 11University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 12Brigham and Women's Hospital, Boston, MA, 13University of Pittsburgh, PITTSBURGH, PA, 14Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 15Georgetown University Hospital/National Institutes of Health, Washington, DC, 16Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 17Johns Hopkins Medicine, Baltimore, MD, 18University of Pennsylvania, Philadelphia, PA, 19Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 20Mayo Clinic Rochester, Rochester, MN, 21Mayo Clinic College of Medicine, Rochester, MN, 22Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 23National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…
  • Abstract Number: 2922 • 2019 ACR/ARP Annual Meeting

    Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis

    Kaitlin Quinn1, Joel S. Rosenblum 2, Casey A. Rimland 3, K Bates Gribbons 4, Mark A. Ahlman 5 and Peter C. Grayson 6, 1Georgetown University Hospital/National Institutes of Health, Washington, DC, 2National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, 3National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) is one of several imaging modalities used in the assessment of patients with large-vessel vasculitis (LVV).  Conventionally PET…
  • Abstract Number: 293 • 2019 ACR/ARP Annual Meeting

    False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign

    Elisa Fernández1, Irene Monjo 2, Gema Bonilla 3, Chamaida Plasencia 4, Maria-Eugenia Miranda-Carus 2, Alejandro Balsa 4 and Eugenio de Miguel 5, 1Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, 2FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, 4Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 5Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. The halo sign is an accepted valid test for the diagnosis…
  • Abstract Number: 372 • 2019 ACR/ARP Annual Meeting

    Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience

    Gozde Kubra Yardımcı 1, Alper Sarı 1, Abdulsamet Erden 2, Ertugrul Cagri Bolek 1, Bayram Farisoğulları 1, Levent Kilic 3, Berkan Armagan 4, Umut Kalyoncu 5, Tuncay Hazırolan 6, Ali İhsan Ertenli 1 and Omer Karadag7, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, 5Hacettepe University Department of Rheumatology, Ankara, Turkey, 6Hacettepe University, Division of Radiology, Ankara, 7Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey

    Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that may involve multiple organ systems. IgG4-RD can also lead to large vessel vasculitis and…
  • Abstract Number: 767 • 2019 ACR/ARP Annual Meeting

    Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains

    Casey A. Rimland1, Kaitlin Quinn 2, Joel S. Rosenblum 3, Mollie Schwartz 4, K Bates Gribbons 5, Elaine Novakovich 6, Antoine Sreih 7, Peter Merkel 7, Mark A. Ahlman 8 and Peter C. Grayson 9, 1National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, 2Georgetown University Hospital/National Institutes of Health, Washington, DC, 3National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, 4University of Maryland, Baltimore, MD, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 6National Institutes of Health, Bethesda, MD, 7University of Pennsylvania, Philadelphia, PA, 8Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, 9National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
  • Abstract Number: 798 • 2019 ACR/ARP Annual Meeting

    Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model

    Gina Montealegre Sanchez1, Adriana de Jesus 1, Jenna Wade 2, Katherine Townsend 1, Arianne Soldatos 3, Alessandra Brofferio 4, Peter C. Grayson 5, Ginger Janow 6 and Raphaela Goldbach-Mansky 1, 1Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, 2Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, 3NIH/NINDS, Bethesda, 4NIH/NHLBI, Bethesda, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD, 6Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, NJ

    Background/Purpose: Deficiency of interleukin-1-receptor antagonist (DIRA) is a rare autoinflammatory disease caused by autosomal recessive loss of function mutations in IL1RN and characterized by early-onset generalized pustulosis,…
  • Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting

    Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity

    Arash Hassantoufighi 1, Rachel Lu-Do1, Mamta Sherchan 1, Christopher Collins 1, Joshpaul Dhillon 2 and Florina Constantinescu 1, 1MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, 2MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC

    Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
  • Abstract Number: 1964 • 2019 ACR/ARP Annual Meeting

    A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)

    Anne Desbois1, Dragos Ciocan 2, David Saadoun 1, Gabriel Perlemuter 3 and Patrice Cacoub 4, 1GHPS, Paris, France, 2Hôpital Antoine Beclere, Clamart, France, 3Hôpital Clamart, Paris, France, 4AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology